
Adtalem Global Education Inc. (NYSE:CVSA – Free Report) – Stock analysts at Zacks Research cut their Q2 2027 earnings per share estimates for Adtalem Global Education in a research report issued to clients and investors on Friday, November 13th. Zacks Research analyst Team now anticipates that the company will earn $2.11 per share for the quarter, down from their previous estimate of $2.38. The consensus estimate for Adtalem Global Education’s current full-year earnings is $9.08 per share. Zacks Research also issued estimates for Adtalem Global Education’s Q4 2027 earnings at $2.38 EPS, FY2027 earnings at $9.04 EPS, Q1 2028 earnings at $2.35 EPS, Q2 2028 earnings at $2.42 EPS, Q3 2028 earnings at $2.57 EPS, Q4 2028 earnings at $2.68 EPS, FY2028 earnings at $10.01 EPS, Q1 2029 earnings at $2.66 EPS and FY2029 earnings at $11.61 EPS.
Adtalem Global Education (NYSE:CVSA – Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The company reported $2.19 EPS for the quarter, beating analysts’ consensus estimates of $1.90 by $0.29. Adtalem Global Education had a return on equity of 21.79% and a net margin of 12.84%. The business had revenue of $511.53 million during the quarter.
Check Out Our Latest Research Report on CVSA
Adtalem Global Education Price Performance
CVSA opened at $118.35 on Monday. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.81 and a quick ratio of 0.81. The company has a market capitalization of $3.94 billion, a price-to-earnings ratio of 16.17, a P/E/G ratio of 0.87 and a beta of 0.70. The firm’s fifty day moving average price is $124.74 and its two-hundred day moving average price is $121.85. Adtalem Global Education has a 1 year low of $86.97 and a 1 year high of $142.13.
Insider Activity at Adtalem Global Education
In other news, CAO Manjunath Gangadharan sold 1,802 shares of the company’s stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $137.18, for a total value of $247,198.36. Following the completion of the transaction, the chief accounting officer directly owned 5,083 shares of the company’s stock, valued at $697,285.94. This represents a 26.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Stephen Beard sold 4,667 shares of the stock in a transaction that occurred on Friday, October 9th. The shares were sold at an average price of $130.77, for a total value of $610,303.59. Following the sale, the chief executive officer directly owned 469,158 shares of the company’s stock, valued at $61,351,791.66. The trade was a 0.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 10,108 shares of company stock valued at $1,331,918. 2.70% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Adtalem Global Education
An institutional investor recently bought a new position in Adtalem Global Education stock. Kendall Capital Management bought a new position in shares of Adtalem Global Education Inc. (NYSE:CVSA – Free Report) during the second quarter, according to its most recent filing with the SEC. The fund bought 11,622 shares of the company’s stock, valued at approximately $1,449,000. Hedge funds and other institutional investors own 98.84% of the company’s stock.
Latest Adtalem Global Education News
Here’s some of the latest news about CVSA:
- Positive Sentiment: Zacks raised its full-year EPS estimates to $9.04 for FY2027, $10.01 for FY2028 and $11.61 for FY2029. It also increased several quarterly forecasts, including Q4 2028 to $2.68 from $2.59. Higher projections point to improving expected earnings over time. MarketBeat report
- Negative Sentiment: Zacks lowered its Q2 2027 EPS estimate to $2.11 from $2.38 and its Q2 2028 estimate to $2.42 from $2.56, indicating weaker expectations for those periods. MarketBeat report
About Adtalem Global Education
Adtalem Global Education is a U.S.-based education company focused primarily on healthcare and professional education. Its institutions offer undergraduate and graduate degree programs, professional training, and online learning for students preparing for careers in fields such as nursing, medicine, veterinary medicine, and business. Its institutions include Chamberlain University, Walden University, the American University of the Caribbean School of Medicine, Ross University School of Medicine, and Ross University School of Veterinary Medicine.
Read More
- Five stocks we like better than Adtalem Global Education
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Adtalem Global Education Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adtalem Global Education and related companies with MarketBeat.com's FREE daily email newsletter.
